. Author manuscript; available in PMC: 2008 May 27.

Published in final edited form as: Schizophr Res. 2007 Mar 9;92(1-3):197–206. doi: 10.1016/j.schres.2007.01.027

Table 1.

Demographic and Clinical Characteristics of Study Groups

	Patients With Schizophrenia (N=25)	Normal Contols (N=28)	d.f.	t	p
Total ICC (ml)	1513.8 ± 105.6	1566.4 ± 140.7	51	1.52	0.134
Age (range)	42.6 ± 8.4 (29–55)	42.0 ± 7.5 (28–55)	51	−0.27	0.787
Handedness	0.78 ± 0.16	0.80 ± 0.18	51	0.52	0.603
SES^a	4.1 ± 0.7	2.0 ± 1.1	51	−7.82	<0.001
Parental SES	2.9 ± 1.4	2.5 ± 1.0	51	−1.14	0.262
WAIS-R, information subscale	10.1 ± 2.6	11.0 ± 1.8	51	1.56	0.126
Medication dose^b (CPZ equiv., mg)	497 ± 258
Symptom onset (years)	22.7 ± 4.1
Duration of illness (years)	19.9 ± 9.6
SAPS total	9.2 ± 3.7
SANS total	12.3 ± 3.9

Higher scores indicating lower SES.

Patients with schizophrenia showed significantly lower SES than controls.

Patients were administered the following medications: [N=5 risperidone, N=4 haloperidol, N=3 ziprasidone; N=3 fluphenazine; N=3 clozapine, N=2 olanzapine; N=1 perphenazine; N=1 chlorpromazine; N=1 olanzapine & ziprasidone; N=1 quetiapine & olanzapine; N=1 risperidone & chlorpromazine].